Japan’s PDMA Shifts Post-heparin Focus Of GMP Inspections Onto Asia
This article was originally published in PharmAsia News
Executive Summary
Japan's Pharmaceutical and Medical Device Agency will focus inspections for compliance with good manufacturing practices predominantly on Asian countries, the agency's inspection specialist, Ryoko Naruse, said during an Osaka seminar
You may also be interested in...
Japanese Regulators Enforcing More Post-Market Surveillance (Part 1 of 2)
TOKYO - As Japan looks to resolve its drug lag with the West, pharmaceutical companies are finding more and more "all cases surveillance" requirements added as conditions for approval by Japan's Ministry of Health, Labor and Welfare
Global Drug Regulators And Manufacturers Grapple With How To Ensure Global Quality Standards (Part 2 Of 2)
[Editor's note: This is part two of a two-part feature on ensuring drug quality, as discussed at the Fifth IFPMA Asian Regulatory Conference in Kuala Lumpur. Part one appeared in PharmAsia News, March 17, 2008.]
Global Drug Regulators And Manufacturers Grapple With How To Ensure Global Quality Standards (Part 1 Of 2)
KUALA LUMPUR, Malaysia - With global resources shrinking and the need for quality control in the drug supply chain greater than ever, regional solutions offer a look at how Asia fits into the regulatory scheme for assessing good manufacturing practices